CYDY Projected Dividend Yield
CytoDyn, Inc. ( OTCBB : CYDY )CytoDyn Inc. is a clinical-stage biotechnology company. Co. is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. Co. has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. 21 YEAR PERFORMANCE RESULTS |
CYDY Dividend History Detail CYDY Dividend News CYDY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |